Jim Simons Cyclacel Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.28 - $0.75 $4,144 - $11,100	14,800 Added 8.67%	185,500 $66,000
Q2 2023 Aug 11, 2023	BUY	$0.52 - $0.76 $520 - $760	1,000 Added 0.59%	170,700 $101,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.15 $728 - $1,494	1,300 Added 0.77%	169,700 $97,000
Q4 2022 Feb 13, 2023	BUY	$0.54 - $21.75 $432 - $17,400	800 Added 0.48%	168,400 $112,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $21.9 $128,658 - $2.29 Million	104,600 Added 166.03%	167,600 $245,000
Q2 2022 Aug 12, 2022	BUY	$6.1 - $7.15 $384,300 - $450,450	63,000 New	63,000 $68,000
Q3 2020 Nov 13, 2020	SELL	$4.81 - $6.49 $825,766 - $1.11 Million	-171,677 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.2 - $7.75 $892,720 - $1.33 Million	171,677 New	171,677 $798,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $4.64M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.